載入中
NASDAQHealthcareMedical - Devices
最新資料
US$0.6109
−US$0.0271 · -4.25%
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
一般交易時段
US$0.6109
−US$0.0271 · -4.25%
盤中時間採用ET。市場資料可能有所延遲。
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
日內區間
目前US$0.6109
52週區間
目前US$0.6109
盤中時間採用ET。市場資料可能有所延遲。
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
日內區間
目前US$0.6109
52週區間
目前US$0.6109
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 470.6萬 USD | 434.6萬 USD | 242.8萬 USD | 37.7萬 USD | 50萬 USD |
| 銷貨成本 | 754.2萬 USD | 826.6萬 USD | 847.8萬 USD | 361.4萬 USD | 58.5萬 USD |
| 毛利 | −283.6萬 USD | −392萬 USD | −605萬 USD | −323.7萬 USD | −8.5萬 USD |
| 研究與開發 | 56.78億 USD | 599.2萬 USD | 725.2萬 USD | 1146.6萬 USD | 929.6萬 USD |
| 銷售、一般及管理費用 | 415.77億 USD | 366.19億 USD | 3565.8萬 USD | 3981.9萬 USD | 1803.8萬 USD |
| 營業費用 | 4680.4萬 USD | 4213.2萬 USD | 4243.2萬 USD | 5293.4萬 USD | 2733.4萬 USD |
| 利息收入 | 38.6萬 USD | 32.2萬 USD | 42.4萬 USD | 8.8萬 USD | — |
| 利息支出 | 2.2萬 USD | 2.6萬 USD | 41.6萬 USD | 8000 USD | 65.9萬 USD |
| 折舊和攤銷 | 87.2萬 USD | 116.7萬 USD | 249.9萬 USD | 193.6萬 USD | 4000 USD |
| 營業利益 | −4964萬 USD | −4605.2萬 USD | −4848.2萬 USD | −5617.1萬 USD | −2741.9萬 USD |
| 淨利 | −5801萬 USD | −4552.9萬 USD | −5266.6萬 USD | −5617.1萬 USD | −2807.8萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI444.97萬0.00%2.3兆 USD0.03%US$381.73-0.05%
iShares Russell 2000 ETFIWM230.7萬0.00%787.4億 USD0.19%US$278.52-0.15%
Vanguard Extended Market ETFVXF182.16萬0.00%954億 USD0.05%US$234.2-0.34%
iShares Russell 2000 Growth ETFIWO88.75萬0.01%139.17億 USD0.24%US$354.48-0.64%
Vanguard Russell 2000 ETFVTWO83.37萬0.00%180億 USD0.06%US$112.5-0.14%
iShares Micro-Cap ETFIWC30.99萬0.02%13.17億 USD0.60%US$182.24-0.42%
Vanguard Russell 2000 Growth ETFVTWG15.84萬0.01%17億 USD0.06%US$258.88-0.62%
iShares Russell 2500 ETFSMMD4.89萬0.00%40.62億 USD0.23%US$86.22-0.08%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
